Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Seikagaku widens FY net loss forecast to ¥2.7 billion on higher R&D costs

Tue, Nov 10, 2026 16:00 JST Seikagaku Corporation (4548.T) Pharmaceutical 中文

Seikagaku Corporation (4548) widened its net loss forecast for the year ending March 2027 to ¥2.7 billion from ¥1.8 billion and its operating loss forecast to ¥2.9 billion from ¥2.05 billion, citing higher R&D spending to prepare for the resubmission of SI-6603.

Revised FY net loss¥2.7 billion
Revised FY operating loss¥2.9 billion
H1 sales¥18.22 billion
FY dividend forecast¥20 per share

The revised forecast keeps sales unchanged at ¥37.1 billion. Ordinary profit is now projected at a loss of ¥650 million, versus a ¥200 million profit previously, and the net loss per share at ¥49.43, versus ¥32.96. The company said its dividend forecast is unchanged. For the year ended March 2026, it posted net profit of ¥1.47 billion.

For the April-September first half, sales rose 1.7% to ¥18.22 billion. The operating loss widened to ¥1.42 billion from ¥557 million a year earlier on higher manufacturing costs and R&D expenses. Ordinary profit rose 13.4% to ¥602 million, helped by sales of investment securities. The company swung to a net loss of ¥1.22 billion from a ¥229 million profit, as tax expenses rose following the reversal of deferred tax assets.

Domestic pharmaceutical sales rose 7.1% to ¥6.25 billion, while overseas pharmaceutical sales fell 35.8% to ¥2.83 billion, mainly on lower shipments of Gel-One to the U.S., attributed chiefly to shipment timing, and of Artz to China, where shipments were temporarily halted for procedures related to a change in materials. The LAL business grew 17.3% to ¥6.78 billion.

The interim dividend was ¥10 per share, with a full-year forecast of ¥20, compared with ¥30 for the previous year.

Next steps: The company plans to file its half-year securities report on Nov. 12, 2026, and post supplementary materials on its website the same day. Dividend payments are scheduled to begin Dec. 2, 2026. Artz shipments to China are scheduled to resume from the third quarter.


Original filings
Related